Mitsubishi UFJ Asset Management Co. Ltd. Purchases 170,772 Shares of Medtronic PLC $MDT

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Medtronic PLC (NYSE:MDT) by 7.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,518,931 shares of the medical technology company’s stock after acquiring an additional 170,772 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.20% of Medtronic worth $219,575,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in MDT. Parkside Financial Bank & Trust raised its holdings in Medtronic by 7.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 7,389 shares of the medical technology company’s stock worth $644,000 after purchasing an additional 495 shares during the last quarter. Keystone Financial Services raised its stake in shares of Medtronic by 15.9% during the second quarter. Keystone Financial Services now owns 8,107 shares of the medical technology company’s stock worth $707,000 after buying an additional 1,115 shares during the last quarter. Aviva PLC lifted its holdings in Medtronic by 94.1% in the second quarter. Aviva PLC now owns 957,789 shares of the medical technology company’s stock valued at $83,490,000 after buying an additional 464,364 shares during the period. True Wealth Design LLC boosted its stake in Medtronic by 49.8% in the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 140 shares during the last quarter. Finally, AE Wealth Management LLC grew its holdings in Medtronic by 17.1% during the 2nd quarter. AE Wealth Management LLC now owns 10,420 shares of the medical technology company’s stock worth $908,000 after acquiring an additional 1,521 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on MDT shares. Citigroup upped their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Mizuho boosted their target price on Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $111.00 price target on shares of Medtronic in a research report on Friday, October 10th. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, November 2nd. Finally, BTIG Research reiterated a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Stock Performance

Shares of Medtronic stock opened at $92.22 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The firm has a market cap of $118.29 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The stock’s 50-day moving average is $94.20 and its 200-day moving average is $89.96. Medtronic PLC has a one year low of $79.29 and a one year high of $99.37.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. The firm had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.1%. The ex-dividend date was Friday, September 26th. Medtronic’s payout ratio is presently 78.24%.

Insider Activity

In related news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of the stock in a transaction on Monday, August 25th. The shares were bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.26% of the stock is owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.